Virtu Financial LLC Purchases New Position in XBiotech Inc. (NASDAQ:XBIT)

Virtu Financial LLC acquired a new position in shares of XBiotech Inc. (NASDAQ:XBIT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 14,735 shares of the biopharmaceutical company’s stock, valued at approximately $58,000.

Other institutional investors have also modified their holdings of the company. Geode Capital Management LLC raised its stake in XBiotech by 5.1% during the 3rd quarter. Geode Capital Management LLC now owns 452,264 shares of the biopharmaceutical company’s stock worth $3,496,000 after acquiring an additional 22,059 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of XBiotech by 2.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,770 shares of the biopharmaceutical company’s stock worth $1,962,000 after purchasing an additional 5,500 shares in the last quarter. State Street Corp increased its position in shares of XBiotech by 10.7% during the third quarter. State Street Corp now owns 224,595 shares of the biopharmaceutical company’s stock worth $1,736,000 after purchasing an additional 21,752 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of XBiotech by 7.5% in the 4th quarter. Bank of New York Mellon Corp now owns 91,060 shares of the biopharmaceutical company’s stock valued at $360,000 after purchasing an additional 6,328 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of XBiotech by 7.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 58,437 shares of the biopharmaceutical company’s stock valued at $452,000 after purchasing an additional 4,298 shares during the period. Hedge funds and other institutional investors own 55.70% of the company’s stock.

XBiotech Stock Up 4.5 %

XBIT opened at $3.24 on Tuesday. XBiotech Inc. has a 52 week low of $2.94 and a 52 week high of $9.96. The business’s 50 day moving average is $3.32 and its two-hundred day moving average is $5.32. The firm has a market cap of $98.78 million, a price-to-earnings ratio of -3.00 and a beta of 1.25.

XBiotech (NASDAQ:XBIT) last announced its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.34) EPS for the quarter.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.